Otophyma: a rare variant of phymatous rosacea

Alcántara-Reifs, Carmen María; Salido‐Vallejo, Rafael; Garnacho‐Saucedo, Gloria; García-Nieto, Antonio Vélez

doi:10.1016/j.amjoto.2016.01.009

Cited by 8 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While otophyma is poorly cited, there are several cases of bilateral ear enlargement with biopsies supporting the diagnosis of otophyma. [1][2][3][4][5][6][7][8][9][10][11][12] These patients were treated with a variety of medical therapies including metronidazole, doxycycline, dapsone, and prednisone without objective verification of improvement. Most literature emphasizes including otophyma in the differential for ear enlargement.…”

Section: Discussionmentioning

confidence: 99%

Optimizing Management of Otophyma: A Case Series Highlighting the Role of Surgical and Retinoid Therapy

et al. 2020

View full text Add to dashboard Cite

Otophyma is a rare condition that can result in conductive hearing loss. Current otophyma literature does not examine validated treatment outcomes for patients. Utilizing a medical and surgical approach to maintain a patent canal can lead to significant objective improvements. The aim of this case series is to describe a combined successful approach in 3 cases from an academic, multidisciplinary center. The main outcomes analyzed were pre and post air-bone gap audiogram analysis and disimpaction frequency. The results showed that post-management, patient 1 had substantial improvement in hearing, recovering 49 dB in his right ear and 25 dB in his left ear, demonstrating near complete air-bone gap closure. Patient 2 showed a similar dermatologic and functional improvement, although objective audiometric assessment related to otophyma could not be performed due to coexisting chronic otitis media and cholesteatoma. Patient 3, in the 12 months prior to comanagement, had 8 bilateral disimpactions, and following comanagement had 2 disimpactions in 23 months. All 3 patients were pleased with the resultant functional and physical appearance following comanagement. By presenting this approach and objective measures of treatment, we hope to improve future clinical decision-making in a rare condition.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimizing Management of Otophyma: A Case Series Highlighting the Role of Surgical and Retinoid Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the literature, there are reported cases with conductive hearing loss in rosacea patients with otophyma mainly due to the obstruction of the external auditory canal by otophyma. 14,15 Since rosacea is thought of as an autoimmune-related inflammatory disease with vascular abnormalities, and the underlying immunologic mechanisms may affect the cochlea of the patients with rosacea, we aimed to evaluate the presence of a sensorineural hearing loss in patients with rosacea in comparison with the healthy control group and also to compare the hearing test results according to the severity of disease among the patient group. To the best of our knowledge, this is the first study that evaluates hearing loss in patients with rosacea.…”

Section: Introductionmentioning

confidence: 99%

“…Although many comorbidities including autoimmune disorders are more in patients with rosacea than healthy controls, to the best of our knowledge, hearing loss in these patients has not been evaluated up to now. In the literature, there are reported cases with conductive hearing loss in rosacea patients with otophyma mainly due to the obstruction of the external auditory canal by otophyma 14,15 . Since rosacea is thought of as an autoimmune‐related inflammatory disease with vascular abnormalities, and the underlying immunologic mechanisms may affect the cochlea of the patients with rosacea, we aimed to evaluate the presence of a sensorineural hearing loss in patients with rosacea in comparison with the healthy control group and also to compare the hearing test results according to the severity of disease among the patient group.…”

Section: Introductionmentioning

confidence: 99%

Assessment of hearing loss in patients with rosacea

Ayvaz

Sivrice

Atay

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Objectives/Aims: Rosacea is not only a skin condition but a systemic inflammatory disease that includes chronic inflammation, vascular alterations, and autoimmunity in pathogenesis. We aimed to evaluate the presence of a sensorineural hearing loss in the patients with rosacea in comparison with the healthy control group and, also to compare the audiometric results according to the severity of disease among the patient group.Methods: Fifty-three patients with erythematelangiectatic or papulopustular type of rosacea and 105 age-and sex-matched healthy controls were included. Each participant had audiometric measurements after a complete ear-nose-throat examination by the same otorhinolaryngologist. Results:The results of air and bone conduction thresholds showed statistically significant differences in particularly high frequencies between the groups in both the right and left ear (for all p < 0.05), but there was no correlation between audiometric measurements and the severity or the type of rosacea (p > 0.05).Conclusions: Regardless of disease severity or type, rosacea patients are likely to have sensorineural hearing loss, and it is important to refer these patients in the early period.

show abstract

“…Rosacea is a chronic inflammatory disease of the skin [ 1 , 2 , 3 ]. The clinical features appear principally in the central region of the face and include the presence of facial erythema, inflammatory papules and pustules, telangiectasia, and edema [ 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Human Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes

Silva-Abreu

Espinoza

Rodríguez-Lagunas

et al. 2017

IJMS

View full text Add to dashboard Cite

Rosacea is the most common inflammatory skin disease. It is characterized by erythema, inflammatory papules and pustules, visible blood vessels, and telangiectasia. The current treatment has limitations and unsatisfactory results. Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptors (PPARs), a nuclear receptor that regulates important cellular functions, including inflammatory responses. The purpose of this study was to evaluate the permeation of PGZ with a selection of penetration enhancers and to analyze its effectiveness for treating rosacea. The high-performance liquid chromatography (HPLC) method was validated for the quantitative determination of PGZ. Ex vivo permeation experiments were realized in Franz diffusion cells using human skin, in which PGZ with different penetration enhancers were assayed. The results showed that the limonene was the most effective penetration enhancer that promotes the permeation of PGZ through the skin. The cytotoxicity studies and the Draize test detected cell viability and the absence of skin irritation, respectively. The determination of the skin color using a skin colorimetric probe and the results of histopathological studies confirmed the ability of PGZ-limonene to reduce erythema and vasodilation. This study suggests new pharmacological indications of PGZ and its possible application in the treatment of skin diseases, namely rosacea.

show abstract

Otophyma: a rare variant of phymatous rosacea

Cited by 8 publications

References 6 publications

Optimizing Management of Otophyma: A Case Series Highlighting the Role of Surgical and Retinoid Therapy

Optimizing Management of Otophyma: A Case Series Highlighting the Role of Surgical and Retinoid Therapy

Assessment of hearing loss in patients with rosacea

Human Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes

Contact Info

Product

Resources

About